Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › sulfonylurea

sulfonylurea

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of sulfonylurea

14 trials tracked of sulfonylurea: 10 in phase 3 or 4 and 4 with published results. The most-cited published study has 252 citations.

14Trials tracked
10Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 1 Phase 3 9 Phase 2 1 Other / NA 3
  1. Phase 3 GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA) Completed · 252 cited
  2. Phase 3 GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea Completed · 126 cited
  3. Phase 3 Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin Completed · 69 cited
  4. Phase 3 A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838) Completed · 56 cited
  5. Phase 4 Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy Completed
  6. Phase 3 Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin Completed
Show 8 more trials
  1. Phase 3 A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus Completed
  2. Phase 3 Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262) Completed
  3. Phase 3 RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes Completed
  4. Phase 3 Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes Completed
  5. Phase 2 The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes Completed
  6. N/A The OBSTACLE Hypoglycemia Study (MK-0000-158) Completed
  7. N/A An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201) Completed
  8. N/A Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk Completed

Showing the 14 most-cited and recently-updated of 14 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review of NHANES data links metformin use to lower mortality and inflammatory markers in type 2 diabetes
Diabetes & Endocrinology
Review of NHANES data links metformin use to lower mortality and inflammatory markers in type 2 diabetes Metformin use linked to lower death risk and better inflammation markers in U.S. adults with diabetes
This review of NHANES 2013-2018 data (2,116 adults) found that metformin use was associated with lower all-cause and cardiovascular mortalit…
New analysis of U.S. adults with diabetes suggests metformin use connects to lower death risk and improved inflammation markers, though more…
medRxiv May 1, 2026